Kathryn Krulisky
Neurology · Salt Lake City, UTNPI 1992294607
Payments from drug & device makers
What this record shows
10 manufacturers reported payments, led by Neuropace, Inc. at 46.1% of the total.
Across 25 payments — averaging $228.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuropace, Inc.$3K
- Livanova USA, Inc.$1K
- DIXI Medical USA Corp$1K
- SK Life Science, Inc.$400
- AstraZeneca$195
- Akcea Therapeutics, Inc.$146
- plus $225 from 4 others
What the payments were for
- Travel & lodging$2,88350%
- Food & beverage$2,83950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuropace, Inc. | 8 | $2,636 |
| Livanova USA, Inc. | 3 | $1,064 |
| DIXI Medical USA Corp | 3 | $1,056 |
| SK Life Science, Inc. | 4 | $400 |
| AstraZeneca | 2 | $195 |
| Akcea Therapeutics, Inc. | 1 | $146 |
| Genentech, Inc. | 1 | $120 |
| UCB, Inc. | 1 | $71 |
| Greenwich Biosciences, Inc. | 1 | $19 |
| Biogen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RNS Neurostimulator Kit$2,588
- VNS Therapy$1,064
- TEGSEDI$146
- XCOPRI$126
How this compares
$5,722 in reported general payments places this provider in the 70th percentile of 157 neurology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 13 | $13,213 |
| Lacosamide | 43 | $5,914 |
| Levetiracetam | 26 | $1,627 |
| Lamotrigine | 73 | $1,275 |
| Levetiracetam ErLevetiracetam | 14 | $505 |
| Clobazam | 20 | $457 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $146 |
| Donepezil Hcl | 17 | $79 |
Paid to pharmacies, not to this prescriber.
Other neurology in Salt Lake City
- Timothy WestSalt Lake City$856K
- Stacey SteevesSalt Lake City$548K
- Amir ArainSalt Lake City$329K
- Mark BrombergSalt Lake City$265K
- April ErwinSalt Lake City$263K
- Albert SmithSalt Lake City$122K
- John FoleySalt Lake City$99K
- Kevin BrennanSalt Lake City$81K
- Lucy DewittSalt Lake City$81K
- Nicholas JohnsonSalt Lake City$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.